AT-1001

AT-1001 is a selective small molecule partial agonist of nicotinic acetylcholine receptors (nAChR) being developed by Astraea Therapeutics for smoking cessation and the treatment of nicotine addiction. Preclinical data indicates that AT-1001 selectively decreases nicotine self-administration and prevents nicotine relapse triggered by stress or environmental cues in animal models. While scientific literature primarily characterizes AT-1001 as a selective ligand for the **alpha-3 beta-4 (α3β4)** nAChR subtype, company pipeline information also identifies it as targeting the **alpha-4 beta-2 (α4β2)** subtype. Its mechanism of action is intended to be distinct from current smoking cessation pharmacotherapies such as varenicline and bupropion, potentially offering a novel therapeutic pathway for managing withdrawal and preventing relapse.

Other names

N-(2-bromophenyl)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine hydrochloride